Peptide Protocol
Peptide Protocol
 App Store

Cerebrolysin: the complete guide

Cerebrolysin is a neurotrophic peptide preparation derived from pig brain, used clinically outside the US for stroke, Alzheimer's disease, and traumatic brain injury. It is a mixture — not a single peptide.

Written by Peptide Protocol Editorial Medically reviewed per our review process Last reviewed
ClassNeurotrophic peptide mixture
Half-lifeVariable (peptide mixture, not a single molecule)
Typical dose5–30 ml per infusion (5–30 mg·ml); IM dosing also used
CategoryNeurology / cognition
Research useStroke recovery, dementia, traumatic brain injury (where approved)
FDA statusNot FDA approved. Approved in many European and Asian countries for stroke, dementia, and TBI.

How Cerebrolysin works

Cerebrolysin is thought to mimic endogenous neurotrophic factor activity, supporting neuronal survival, synaptic plasticity, and neurogenesis. Its specific active components remain incompletely characterized.

Typical Cerebrolysin dosage

Commonly reported research ranges: 5–30 ml per infusion (5–30 mg·ml); IM dosing also used.

Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.

Administration

Cerebrolysin is taken orally — no reconstitution is required. Follow the manufacturer's guidance for liquid or capsule dosing.

Half-life and administration frequency

Variable (peptide mixture, not a single molecule).

This half-life informs how often Cerebrolysin is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.

Reported side effects

This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.

Common Cerebrolysin stacks

Storage and handling

Pre-dissolved solution at room temperature, protected from light.

FDA and regulatory status

Not FDA approved. Approved in many European and Asian countries for stroke, dementia, and TBI.

Cerebrolysin clinical trials and evidence

For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.

Track your Cerebrolysin protocol on iPhone

Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.

See the app →

Frequently asked questions

What is Cerebrolysin?

Cerebrolysin is a neurotrophic peptide preparation derived from pig brain, used clinically outside the US for stroke, Alzheimer's disease, and traumatic brain injury. It is a mixture — not a single peptide.

How does Cerebrolysin work?

Cerebrolysin is thought to mimic endogenous neurotrophic factor activity, supporting neuronal survival, synaptic plasticity, and neurogenesis. Its specific active components remain incompletely characterized.

What is a typical Cerebrolysin dose?

Commonly reported ranges are 5–30 ml per infusion (5–30 mg·ml); IM dosing also used. This is research information, not a recommendation — dosing should be individualized under clinical guidance.

What is the half-life of Cerebrolysin?

Variable (peptide mixture, not a single molecule). This influences how often it is taken.

Does Cerebrolysin require reconstitution?

Cerebrolysin is not handled as a standard lyophilized injectable reconstitution page in this database. Follow the manufacturer, study protocol, or clinician instructions for the specific formulation.

What are the side effects of Cerebrolysin?

Injection-site or infusion reactions; Agitation or dizziness (infrequent); Contraindicated in severe renal impairment.

Is Cerebrolysin FDA approved?

Not FDA approved. Approved in many European and Asian countries for stroke, dementia, and TBI.

Are there clinical trials for Cerebrolysin?

Registered or published clinical-trial sources for Cerebrolysin are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.

References

  1. Cerebrolysin literature (PubMed) — National Library of Medicine. Primary research across stroke, dementia, and TBI indications
  2. CASTA & CARS-2 trials in acute ischemic stroke — PubMed. Pivotal clinical trials in ischemic stroke
  3. Cerebrolysin clinical trial records — ClinicalTrials.gov. Registered studies across neurological indications

Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.

Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.